Close Menu

Grail

The deal, which was approved by the boards of directors of both companies, is expected to close in the second half of 2021, pending customary conditions.

At the AACR annual meeting, researchers shared detection rate data for multi-cancer screening tests from Grail and Thrive Earlier Detection.

A roundup of some of the precision oncology-focused research presented at the Gastrointestinal Cancer Symposium in San Francisco, Jan. 23 to 25.

A collection of biomarker- and genomic testing-driven precision oncology research presented at the European Society of Medical Oncology Congress.

The company reported that its genome-wide methylation approach could detect 77 percent of stage II cancers in its ongoing case-control CCGA study.

During its earnings call this week, the liquid biopsy firm said it is planning a 10,000-patient trial to test its Lunar assay for colorectal cancer screening.

Take2 was founded by Chinese University of Hong Kong researchers and will commercialize a cell-free DNA test for early cancer detection.

The company presented new data on the performance of a multi-pronged liquid biopsy assay in detecting colorectal cancers across a range of clinical stages.

Though there are few direct hints at how the company plans to translate its findings to a clinical test, its early data has captured the attention of the cancer community.